| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8945212 | Gynecologic Oncology | 2018 | 11 Pages |
Abstract
These results provide a preclinical rationale for improved treatment modalities using olaparib as an effective radiosensitizer in HGSOC, particularly in tumors with BRCA1-deficiencies.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Yue Bi, Ioannis I. Verginadis, Souvik Dey, Lilie Lin, Linlang Guo, Yanfang Zheng, Constantinos Koumenis,